Using established immunosuppressant therapy effectively: Lessons from the measurement of mycophenolic acid plasma concentrations

Therapeutic Drug Monitoring

Volumn 26, Issue 4, 2004, Pages 347-351

  Shaw, Leslie M ^a   Nawrocki, Arthur ^a   Korecka, Magdalena ^a   Solari, Sandra ^a   Kang, Juseop ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Immunosuppressants; Mycophenolic acid; Plasma concentrations

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AREA UNDER THE CURVE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG MONITORING; ENTEROHEPATIC CIRCULATION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SHORT SURVEY;

ADRENAL CORTEX HORMONES; CALCINEURIN; COHORT STUDIES; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; ENTEROHEPATIC CIRCULATION; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; SIROLIMUS; TIME FACTORS; TRANSPLANTATION IMMUNOLOGY;

EID: 3342958747     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200408000-00002     Document Type: Short Survey

References (41)

1. UNOS. 2002 Annual Roport of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: transplant data 1992-2001 [internet]. Rockville (MD): HHS/HRSA/OSP/DOT; 2003 [modified Feb 18, 2003]. Available from http://www.optn.org/data/annual_Report.asp.
2. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57:307-313.
3. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
4. Magee C, Pascual M. The growing problem of chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:994-996.
5. Takahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant Proc. 1995;27:1421-1424.
6. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- phannacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
7. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
8. Nicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/ pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem. 1998;31:329-333.
9. DeNofrio D, Loh E, Kao A, et al. Mycophenolic acid concentrations are associated with cardiac allograft rejection. J Heart Lung Transplant. 2000;19:1071-1076.
10. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759-768.
11. Yamani MH, Starling RC, Goormastic M, et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation. 2000;69:2326-2330.
12. Shaw LM, Holt D, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
13. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
14. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine: a bio-pharmaceutical risk factor for chronic renal allograft rejection. Transplantation. 1996;62:599-606.
15. Fitzsimmons WE, Bekersky I, Dressler D. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc. 1998;30:1359-1364.
16. Neylan J, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation. 1997;64:1277-1282.
17. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol. 2000;40:624-633.
18. Pescovitz MD, Guasch A, Gaston RPR, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African_American and Caucasian male and female stable renal allograft recipients. Am J Transplant. 2003;3:1581-1586.
19. Tukey RH, Strassburg CP. Human UDP-glucuronyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol. 2000;40:581-616.
20. Mackenzie PI. Identification of uridine diphosphate glucuronosytransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit. 2000;22:10-13.
21. Shipkova M, Strassburg CP, Braun F, et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol. 2001;132:1027-1034.
22. Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol. 2001;52:605-609.
23. Soldin SJ, Steele BW. Mini-review: therapeutic drug monitoring in pediatrics. Clin Biochem. 2000;33:333-335.
24. Strassburg CP, Vogel A, Kneip S, et al. Polymorphisms of the human UDP-glucuronyltransferase (UGT) 1A7 gene in colorectal cancer. Gut. 2002;50:851-856.
25. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
26. Funaki T. Enterohepatic circulation model for population phannacokinetic analysis. J Pharm Pharmacol. 1999;51:1143-1148.
27. Premaud A, Debord J, Rousseau A, et al. A double-absorption pharmacokinetic model for mycophenolate in de novo renal transplant patients. [Abstract] Ther Drug Monit. 2003;25:535.
28. Roberts MS, Magnusson BM, Burczynski FJ, et al. Enterohepatic circulation. Physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet. 2002;41:751-790.
29. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
30. Shaw LM, Mick R, Nowak I, et al. brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38:268-275.
31. Meier-Kriesche HU, Shaw LM, Korecka M, et al. Pharmacokientics of mycophenolic acid in renal insufficiency. Ther Drug Monit. 2000;22:27-30.
32. Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol. 2001;41:268-276.
33. Kaplan B, Meier-Kriesche H-U. Mycophenolic acid pharmacokinetics in patients with renal insufficiency. In MPA Pharmacokinetics. Roche Phanna, 2004.
34. Kaplan B, Gruber SA, Nallamathou R, et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998;65:1127-1129.
35. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002;62:1060-1067.
36. Goldberg LR, DeNofrio D, Nawrocki A, et al. Early mycophenolic acid concentrations predict acute rejection in the first three months following heart transplantation [Abstract]. Am J Transplant. 2003;3:385.
37. Smak Gregoor PJH, de Sevaux RG, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603-1606.
38. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000;14:100-104.
39. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002;74.
40. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
41. Wieland E, Shipkova M, Schellhas U, et al. Induction of cytokine release by the acyl-glucuronide of mycophenolic acid: a link to side effects? Clin Biochem. 2000;33:107-113.